LATITUDE: A phase III, double-blind, randomized trial of androgen deprivation therapy with abiraterone acetate plus prednisone or placebos in newly diagnosed high-risk metastatic hormone-naive prostate cancer.

2017 ◽  
Vol 35 (15_suppl) ◽  
pp. LBA3-LBA3 ◽  
Author(s):  
Karim Fizazi ◽  
Namphuong Tran ◽  
Luis Enrique Fein ◽  
Nobuaki Matsubara ◽  
Alfredo Rodríguez Antolín ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
High Risk ◽  
Randomized Trial ◽  
Abiraterone Acetate ◽  
Phase Iii ◽  
Newly Diagnosed ◽  
Double Blind ◽  
Daily News ◽  
Online Supplement ◽  
Final Text

LBA3 The full, final text of this abstract will be available at abstracts.asco.org at 7:30 AM (EDT) on Saturday, June 3, 2017, and in the Annual Meeting Proceedings online supplement to the June 20, 2017, issue of the Journal of Clinical Oncology. Onsite at the Meeting, this abstract will be printed in the Sunday edition of ASCO Daily News.

Interim analysis (IA) results of COU-AA-302, a randomized, phase III study of abiraterone acetate in chemotherapy-naive patients (pts) with metastatic castration-resistant prostate cancer (mCRPC).

2012 ◽  
Vol 30 (15_suppl) ◽  
pp. LBA4518-LBA4518
Author(s):  
Charles J. Ryan ◽  
Matthew Raymond Smith ◽  
Johann Sebastian De Bono ◽  
Arturo Molina ◽  
Christopher Logothetis ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Interim Analysis ◽  
Abiraterone Acetate ◽  
Phase Iii ◽  
Castration Resistant Prostate Cancer ◽  
Daily News ◽  
Online Supplement ◽  
Castration Resistant ◽  
Phase Iii Study ◽  
Final Text

LBA4518 The full, final text of this abstract will be available at abstract.asco.org at 12:01 AM (EDT) on Saturday, June 2, 2012, and in the Annual Meeting Proceedings online supplement to the June 20, 2012, issue of Journal of Clinical Oncology. Onsite at the Meeting, this abstract will be printed in the Saturday edition of ASCO Daily News.

RTOG 0825: Phase III double-blind placebo-controlled trial evaluating bevacizumab (Bev) in patients (Pts) with newly diagnosed glioblastoma (GBM).

2013 ◽  
Vol 31 (15_suppl) ◽  
pp. 1-1 ◽  
Author(s):  
Mark R. Gilbert ◽  
James Dignam ◽  
Minhee Won ◽  
Deborah T. Blumenthal ◽  
Michael A. Vogelbaum ◽  
...  
Keyword(s):  
Annual Meeting ◽  
Controlled Trial ◽  
Phase Iii ◽  
Newly Diagnosed ◽  
Double Blind ◽  
Daily News ◽  
Double Blind Placebo ◽  
Online Supplement ◽  
Newly Diagnosed Glioblastoma ◽  
Final Text

1 The full, final text of this abstract will be available at abstract.asco.org at 7:30 AM (EDT) on Sunday, June, 2, 2013, and in the Annual Meeting Proceedings online supplement to the June 20, 2013, issue of Journal of Clinical Oncology. Onsite at the Meeting, this abstract will be printed in the Sunday edition of ASCO Daily News.

Duration of androgen deprivation therapy in high-risk prostate cancer: A randomized trial.

2013 ◽  
Vol 31 (15_suppl) ◽  
pp. LBA4510-LBA4510 ◽  
Author(s):  
Abdenour Nabid ◽  
Nathalie Carrier ◽  
André-Guy Martin ◽  
Jean-Paul Bahary ◽  
Luis Souhami ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
High Risk ◽  
Randomized Trial ◽  
Annual Meeting ◽  
Clinical Oncology ◽  
Daily News ◽  
Online Supplement ◽  
High Risk Prostate Cancer ◽  
Risk Prostate Cancer ◽  
Final Text

LBA4510 The full, final text of this abstract will be available at abstract.asco.org at 7:30 AM (EDT) on Monday, June 3, 2013, and in the Annual Meeting Proceedings online supplement to the June 20, 2013, issue of Journal of Clinical Oncology. Onsite at the Meeting, this abstract will be printed in the Monday edition of ASCO Daily News.

Updated analysis of the phase III, double-blind, randomized, multinational study of radium-223 chloride in castration-resistant prostate cancer (CRPC) patients with bone metastases (ALSYMPCA).

2012 ◽  
Vol 30 (15_suppl) ◽  
pp. LBA4512-LBA4512 ◽  
Author(s):  
Chris Parker ◽  
Sten Nilsson ◽  
Daniel Heinrich ◽  
Joe M. O'Sullivan ◽  
Sophie D. Fossa ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Phase Iii ◽  
Multinational Study ◽  
Castration Resistant Prostate Cancer ◽  
Double Blind ◽  
Daily News ◽  
Online Supplement ◽  
Castration Resistant ◽  
Radium 223 ◽  
Final Text

LBA4512 The full, final text of this abstract will be available at abstract.asco.org at 12:01 AM (EDT) on Monday, June 4, 2012, and in the Annual Meeting Proceedings online supplement to the June 20, 2012, issue of Journal of Clinical Oncology. Onsite at the Meeting, this abstract will be printed in the Monday edition of ASCO Daily News.

Phase III randomized trial of definitive chemoradiotherapy (CRT) with FOLFOX or cisplatin and fluorouracil in esophageal cancer (EC): Final results of the PRODIGE 5/ACCORD 17 trial.

2012 ◽  
Vol 30 (15_suppl) ◽  
pp. LBA4003-LBA4003
Author(s):  
Thierry Conroy ◽  
Marie-Pierre Galais ◽  
Jean Luc Raoul ◽  
Olivier Bouche ◽  
Sophie Gourgou-Bourgade ◽  
...  
Keyword(s):  
Esophageal Cancer ◽  
Randomized Trial ◽  
Annual Meeting ◽  
Clinical Oncology ◽  
Phase Iii ◽  
Definitive Chemoradiotherapy ◽  
Daily News ◽  
Online Supplement ◽  
Final Text

LBA4003 The full, final text of this abstract will be available at abstract.asco.org at 12:01 AM (EDT) on Saturday, June 2, 2012, and in the Annual Meeting Proceedings online supplement to the June 20, 2012, issue of Journal of Clinical Oncology. Onsite at the Meeting, this abstract will be printed in the Saturday edition of ASCO Daily News.

Incorporation of bevacizumab in the treatment of recurrent and metastatic cervical cancer: A phase III randomized trial of the Gynecologic Oncology Group.

2013 ◽  
Vol 31 (15_suppl) ◽  
pp. 3-3
Author(s):  
Krishnansu Sujata Tewari ◽  
Michael Sill ◽  
Harry J. Long ◽  
Lois M. Ramondetta ◽  
Lisa Michelle Landrum ◽  
...  
Keyword(s):  
Cervical Cancer ◽  
Randomized Trial ◽  
Annual Meeting ◽  
Gynecologic Oncology ◽  
Phase Iii ◽  
Gynecologic Oncology Group ◽  
Oncology Group ◽  
Daily News ◽  
Online Supplement ◽  
Final Text

3 The full, final text of this abstract will be available at abstract.asco.org at 7:30 AM (EDT) on Sunday, June, 2, 2013, and in the Annual Meeting Proceedings online supplement to the June 20, 2013, issue of Journal of Clinical Oncology. Onsite at the Meeting, this abstract will be printed in the Sunday edition of ASCO Daily News.

A phase III randomized trial of chemoimmunotherapy comprising gemcitabine and capecitabine with or without telomerase vaccine GV1001 in patients with locally advanced or metastatic pancreatic cancer.

2013 ◽  
Vol 31 (15_suppl) ◽  
pp. LBA4004-LBA4004 ◽  
Author(s):  
Gary William Middleton ◽  
Juan W. Valle ◽  
Jonathan Wadsley ◽  
David Propper ◽  
Fareeda Y. Coxon ◽  
...  
Keyword(s):  
Pancreatic Cancer ◽  
Randomized Trial ◽  
Annual Meeting ◽  
Clinical Oncology ◽  
Locally Advanced ◽  
Phase Iii ◽  
Metastatic Pancreatic Cancer ◽  
Daily News ◽  
Online Supplement ◽  
Final Text

LBA4004 The full, final text of this abstract will be available at abstract.asco.org at 7:30 AM (EDT) on Monday, June, 3, 2013, and in the Annual Meeting Proceedings online supplement to the June 20, 2013, issue of Journal of Clinical Oncology. Onsite at the Meeting, this abstract will be printed in the Monday edition of ASCO Daily News.

Randomized, double-blind, phase III trial of pazopanib versus placebo in women who have not progressed after first-line chemotherapy for advanced epithelial ovarian, Fallopian tube, or primary peritoneal cancer (AOC): Results of an international intergroup trial (AGO-OVAR16).

2013 ◽  
Vol 31 (15_suppl) ◽  
pp. LBA5503-LBA5503
Author(s):  
Andreas Du Bois ◽  
Anne Floquet ◽  
Jae Weon Kim ◽  
Jörn Rau ◽  
Jose Maria Del Campo ◽  
...  
Keyword(s):  
Phase Iii ◽  
First Line ◽  
Double Blind ◽  
Daily News ◽  
Phase Iii Trial ◽  
Online Supplement ◽  
Peritoneal Cancer ◽  
Intergroup Trial ◽  
Final Text ◽  
Line Chemotherapy

LBA5503 The full, final text of this abstract will be available at abstract.asco.org at 7:30 AM (EDT) on Saturday, June 1, 2013, and in the Annual Meeting Proceedings online supplement to the June 20, 2013, issue of Journal of Clinical Oncology. Onsite at the Meeting, this abstract will be printed in the Saturday edition of ASCO Daily News.

Intermittent (IAD) versus continuous androgen deprivation (CAD) in hormone sensitive metastatic prostate cancer (HSM1PC) patients (pts): Results of S9346 (INT-0162), an international phase III trial.

2012 ◽  
Vol 30 (15_suppl) ◽  
pp. 4-4 ◽  
Author(s):  
Maha Hussain ◽  
Catherine M. Tangen ◽  
Celestia S. Higano ◽  
E. David Crawford ◽  
Glenn Liu ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Annual Meeting ◽  
Clinical Oncology ◽  
Metastatic Prostate Cancer ◽  
Phase Iii ◽  
Daily News ◽  
Phase Iii Trial ◽  
Online Supplement ◽  
Hormone Sensitive ◽  
Final Text

4 The full, final text of this abstract will be available at abstract.asco.org at 12:01 AM (EDT) on Sunday, June 3, 2012, and in the Annual Meeting Proceedings online supplement to the June 20, 2012, issue of Journal of Clinical Oncology. Onsite at the Meeting, this abstract will be printed in the Sunday edition of ASCO Daily News.

Sign in / Sign up

Export Citation Format

Share Document